Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a simple swab identify ICU patients who spread superbugs?

NCT ID NCT07685132

Knowledge-focused Sponsor: Hospital Italiano de Buenos Aires Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 06, 2026 · Last updated Jul 07, 2026 · Updated 1 time

Summary

This study looks at ICU patients who carry carbapenem-resistant bacteria in their gut. Researchers want to see if patients with higher bacterial loads are more likely to contaminate their surroundings and pass the bacteria to others. By measuring bacteria levels in rectal swabs and testing nearby surfaces, the study aims to find ways to better target infection control efforts.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could help identify ICU patients who are most likely to spread drug-resistant bacteria, allowing hospitals to target cleaning and isolation efforts more effectively.
What could go wrong
This is an observational study, not a treatment trial, so it will not directly change patient care. The findings may not apply to other hospitals or bacteria types.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

Jan 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult patients hospitalized in the Adult Intensive Care Unit of Hospital Italiano de Buenos Aires during the study period, with a positive surveillance rectal swab for carbapenemase-producing Enterobacterales detected through the institutional infection control surveillance program.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria * Age 18 years or older. * Hospitalized in the Adult Intensive Care Unit of Hospital Italiano de Buenos Aires during the study period. * Positive surveillance rectal swab for carbapenemase-producing Enterobacterales. Exclusion Criteria -Patients colonized or infected with carbapenemase-producing Enterobacterales who remained in the same room for less than 48 hours.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Antimicrobial resistance (AMR) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

nosocomial infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Antimicrobial resistance (AMR) Carbapenem-resistant enterobacteriaceae colonization Healthcare-associated infections (HAIS)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Hospital Italiano de Buenos Aires

    Buenos Aires, Buenos Aires F.D., 1199, Argentina

More trials for these conditions

Other studies related to the condition(s) this trial covers.